Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Starling OncologySTLNW -9.09%61 Dividend Payout Ratio is 0.00 as of Mar. 2026. GuruFocus rates STLNW with a GF Score™ of 61/100. The stock has 4 warning signs investors should review. Among 243 Healthcare Providers & Services companies, Starling Oncology ranks worse than 411522.22% on this metric.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Starling Oncology's Dividend Payout Ratio for the
months ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Starling Oncology's Dividend Payout Ratio or its related term are showing as below:
STLNW's Dividend Payout Ratio is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 0.41 * Ranked among companies with meaningful Dividend Payout Ratio only.
Starling Oncology (NAS:STLNW) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Starling Oncology Dividend Payout Ratio Related Terms
Starling Oncology Dividend Payout Ratio Historical Data
* Premium members only.
The historical data trend for Starling Oncology's Dividend Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STLNW vs SRTA, CCRN, CYH: Dividend Payout Ratio Comparison
For the Medical Care Facilities subindustry, Starling Oncology's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Starling Oncology Dividend Payout Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Starling Oncology's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where Starling Oncology's Dividend Payout Ratio falls into.
Starling Oncology Dividend Payout Ratio Calculation
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
Starling Oncology's Dividend Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Starling Oncology (STLNW) has a Dividend Payout Ratio of 0.00 as of Mar. 2026. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Starling Oncology and its competitors. According to the industry distribution chart, Starling Oncology ranks #999999 out of 243 companies in the Healthcare Providers & Services industry.
Is Starling Oncology's Dividend Payout Ratio too high?
Starling Oncology's current Dividend Payout Ratio is 0.00. Based on the distribution chart, Starling Oncology ranks #999999 out of 243 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Starling Oncology has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Starling Oncology's Dividend Payout Ratio compare to SRTA and CCRN?
According to the Healthcare Providers & Services industry distribution chart, Starling Oncology ranks #999999 out of 243 companies for Dividend Payout Ratio. This places Starling Oncology in the lower half of its industry. The industry median Dividend Payout Ratio is 0.41. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Healthcare Providers & Services company?
The median Dividend Payout Ratio among Healthcare Providers & Services companies is 0.41, based on 243 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Starling Oncology and its competitors. For the Healthcare Providers & Services industry, the median Dividend Payout Ratio is 0.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Starling Oncology's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Starling Oncology stock overvalued right now?
Starling Oncology (STLNW) has a current Dividend Payout Ratio of 0.00. The current Dividend Payout Ratio is 0.00. Starling Oncology's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Starling Oncology (STLNW), the current Dividend Payout Ratio is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
61GF Score
Get the complete analysis for STLNW
Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STLNW has been successfully added to your 
